Clinical Trials Logo

Gene Therapy clinical trials

View clinical trials related to Gene Therapy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03520712 Active, not recruiting - Hemophilia A Clinical Trials

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

GENEr8-AAV5+
Start date: April 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, single dose study to determine the safety of valoctocogene roxaparvovec (an Adenovirus-Associated Virus (AAV) based gene therapy vector) in severe Hemophilia A patients with pre-existing antibodies against AAV5.

NCT ID: NCT03311503 Active, not recruiting - Gene Therapy Clinical Trials

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Start date: January 19, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years and be followed for 2 years post-infusion on this protocol, then followed long-term on a separate long-term follow-up protocol. Enrollment of subjects will be agreed upon by representatives of both sites. Data will be collected uniformly from both sites through an electronic capture system and key laboratory studies will be centralized. Harvest, cellular manufacturing and infusion will occur at each site using the same SOPs. Key aspects of cellular product characterization will be centralized